RuiRong Yuan, MD, PhD
Department of Medicine, VA Medical Center, UMDNJ-New Jersey Medical School, Newark, New Jersey, USA
Dr. RuiRong Yuan is a U.S. board certified and licensed Medical Oncologist. She joined Daiichi Sankyo, Inc. in Dec. 2010 as the Head of Oncology Therapeutics and serves as Chair of Global Medical Affairs for Tivantinib, a C-Met inhibitor. She designed and executed multiple global clinical studies (Phase I-III & IIIb) and directed life cycle management of RAD001. She and her team supported regulatory filing of RAD001 in patients with RCC.
Dr. Yuan completed her initial medical oncology and tumor immunology training at the premier cancer institute in China, the Cancer Hospital & Cancer Research Institute of the Chinese Academy of Medical Sciences, where she later became an attending physician in oncology (1988). Her research on the prediction of lymphoma recurrence was awarded the Swiss national prize for cancer research in 1993. Dr. Yuan subsequently accepted an immunology research position at Albert Einstein College of Medicine (AECOM), NY. While there, she elucidated how isotypes of anti-cryptococcus antibodies dictate their biological functions, which was recognized by an award of the Aaron Diamond Biology Research Fellowship. These findings led to the clinical exploration of IgG antibodies as therapy for opportunistic fungal infections in cancer and AIDS patients. In order to continue clinical practice and research in the U.S., Dr. Yuan retrained in internal medicine at Jacobi Medical Center, AECOM, and in a clinical fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center. Following completion of her fellowship, Dr. Yuan was appointed Assistant Professor at UMDNJ-New Jersey Medical School and served as Chief of the Tumor and Neuroimmunology research laboratories in 2003. Several new therapeutic strategies were developed in her lab, which are currently being translated into early clinical studies. She holds 6 patents related to either cancer treatment or autoimmune disease therapy.
She is one of the founding members of the Chinese American Hematologist and Oncologist Network and served as its president in 2007-2008 (www.cahon.org). She is the managing editor of the Journal of Hematology & Oncology, Editor-in-Chief of China Medical Tribune Oncology Overseas Column (CMT) and serves as an editor for the Journal of Chinese Clinical Oncology.